ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 089,40
-0,64%
Dow Jones
39 826,85
-0,12%
DAX
18 687,47
-0,21%
Brent Oil
82,285
-0,19%
Bitcoin
70 107,65
-0,03%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Cabaletta Bio Inc (CABA)

  7. Cabaletta Bio Inc (CABA) Actualités

CABA

Cabaletta Bio (CABA)

Cabaletta Bio Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CABA
DateHeureSourceTitreSymboleSociété
15/05/202413h53Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CABACabaletta Bio Inc
15/05/202413h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CABACabaletta Bio Inc
15/05/202413h00GlobeNewswire Inc.Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CABACabaletta Bio Inc
13/05/202414h00GlobeNewswire Inc.Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQNASDAQ:CABACabaletta Bio Inc
21/03/202412h00GlobeNewswire Inc.Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:CABACabaletta Bio Inc
20/03/202412h00GlobeNewswire Inc.Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic SclerosisNASDAQ:CABACabaletta Bio Inc
04/03/202423h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CABACabaletta Bio Inc
27/02/202414h00GlobeNewswire Inc.Cabaletta Bio to Participate in Upcoming Investor Conferences in MarchNASDAQ:CABACabaletta Bio Inc
14/02/202415h20Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CABACabaletta Bio Inc
01/02/202422h30GlobeNewswire Inc.Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of MyositisNASDAQ:CABACabaletta Bio Inc
31/01/202414h00GlobeNewswire Inc.Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:CABACabaletta Bio Inc
08/01/202413h00GlobeNewswire Inc.Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic SclerosisNASDAQ:CABACabaletta Bio Inc
02/01/202414h00GlobeNewswire Inc.Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:CABACabaletta Bio Inc
29/11/202312h18IH Market NewsAmazon Unveils Innovative Services, Okta Discloses Data Breach, Textron Plans 2% Global Workforce Reduction, and MoreNASDAQ:CABACabaletta Bio Inc
28/11/202322h30GlobeNewswire Inc.Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:CABACabaletta Bio Inc
28/11/202320h59Dow Jones NewsCabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T DrugsNASDAQ:CABACabaletta Bio Inc
20/11/202322h16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CABACabaletta Bio Inc
09/11/202313h00GlobeNewswire Inc.Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:CABACabaletta Bio Inc
06/11/202314h15Business WireCellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle PlatformNASDAQ:CABACabaletta Bio Inc
06/11/202313h55Dow Jones NewsCabaletta Bio Gets FDA OK to Study CABA-201 in Generalized Myasthenia GravisNASDAQ:CABACabaletta Bio Inc
06/11/202313h00GlobeNewswire Inc.Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia GravisNASDAQ:CABACabaletta Bio Inc
30/10/202313h00GlobeNewswire Inc.Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in NovemberNASDAQ:CABACabaletta Bio Inc
02/10/202313h00GlobeNewswire Inc.Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201NASDAQ:CABACabaletta Bio Inc
19/09/202314h00GlobeNewswire Inc.Cabaletta Bio to Participate in Upcoming Investor Conferences in SeptemberNASDAQ:CABACabaletta Bio Inc
30/08/202314h00GlobeNewswire Inc.Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in SeptemberNASDAQ:CABACabaletta Bio Inc
22/08/202314h00GlobeNewswire Inc.Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201NASDAQ:CABACabaletta Bio Inc
10/08/202313h57Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CABACabaletta Bio Inc
10/08/202313h00GlobeNewswire Inc.Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:CABACabaletta Bio Inc
24/07/202314h00GlobeNewswire Inc.Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of DirectorsNASDAQ:CABACabaletta Bio Inc
21/06/202322h39Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CABACabaletta Bio Inc
 Showing the most relevant articles for your search:NASDAQ:CABA

Dernières Valeurs Consultées

COIN
TRATETH
Tratok
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés